

Markus Chmielewski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2083036/publications.pdf>

Version: 2024-02-01

33
papers

3,558
citations

257429

24
h-index

454934

30
g-index

33
all docs

33
docs citations

33
times ranked

4170
citing authors

#	ARTICLE	IF	CITATIONS
1	IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors. <i>Molecular Therapy</i> , 2022, 30, 593-605.	8.2	18
2	CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells. <i>Nature Communications</i> , 2021, 12, 240.	12.8	28
3	TRUCKS, the fourth generation CAR T cells: Current developments and clinical translation. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e84.	0.9	85
4	FimH-based display of functional eukaryotic proteins on bacteria surfaces. <i>Scientific Reports</i> , 2019, 9, 8410.	3.3	3
5	Depletion of Collagen IX Alpha1 Impairs Myeloid Cell Function. <i>Stem Cells</i> , 2018, 36, 1752-1763.	3.2	10
6	CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma. <i>Molecular Therapy</i> , 2018, 26, 1906-1920.	8.2	38
7	TRUCKs with IL-18 payload: Toward shaping the immune landscape for a more efficacious CAR T-cell therapy of solid cancer. <i>Advances in Cell and Gene Therapy</i> , 2018, 1, e7.	0.9	11
8	CAR T Cells Releasing IL-18 Convert to T-Bet ^{high} FoxO1 ^{low} Effectors that Exhibit Augmented Activity against Advanced Solid Tumors. <i>Cell Reports</i> , 2017, 21, 3205-3219.	6.4	282
9	Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma. <i>Frontiers in Immunology</i> , 2017, 8, 1125.	4.8	66
10	Superior Therapeutic Index in Lymphoma Therapy: CD30+ CD34+ Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack. <i>Molecular Therapy</i> , 2016, 24, 1423-1434.	8.2	62
11	Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity. <i>Journal of Immunology</i> , 2016, 196, 759-766.	0.8	164
12	TRUCKs: the fourth generation of CARs. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1145-1154.	3.1	473
13	Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer. <i>Journal of the National Cancer Institute</i> , 2015, 107, 364.	6.3	34
14	Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. <i>Immunological Reviews</i> , 2014, 257, 83-90.	6.0	275
15	Efficacy of CAR T-cell Therapy in Large Tumors Relies upon Stromal Targeting by IFN γ . <i>Cancer Research</i> , 2014, 74, 6796-6805.	0.9	70
16	Adoptive Immunotherapy with Redirected T Cells Produces CCR7 ⁺ Cells That Are Trapped in the Periphery and Benefit from Combined CD28-OX40 Costimulation. <i>Human Gene Therapy</i> , 2013, 24, 259-269.	2.7	49
17	T Cells Expressing a Chimeric Antigen Receptor That Binds Hepatitis B Virus Envelope Proteins Control Virus Replication in Mice. <i>Gastroenterology</i> , 2013, 145, 456-465.	1.3	180
18	Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. <i>Frontiers in Immunology</i> , 2013, 4, 371.	4.8	115

#	ARTICLE	IF	CITATIONS
19	CAR's made it to the pancreas. <i>Oncolmmunology</i> , 2012, 1, 1387-1389.	4.6	1
20	OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4 ⁺ T cells. <i>Oncolmmunology</i> , 2012, 1, 458-466.	4.6	159
21	Depletion of annexin A5, annexin A6, and collagen X causes no gross changes in matrix vesicle-mediated mineralization, but lack of collagen X affects hematopoiesis and the Th1/Th2 response. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2399-2412.	2.8	34
22	CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1269-1277.	4.2	99
23	Chimeric Antigen Receptors for T-Cell Based Therapy. <i>Methods in Molecular Biology</i> , 2012, 907, 645-666.	0.9	33
24	T Cells That Target Carcinoembryonic Antigen Eradicate Orthotopic Pancreatic Carcinomas Without Inducing Autoimmune Colitis in Mice. <i>Gastroenterology</i> , 2012, 143, 1095-1107.e2.	1.3	113
25	Redirected T Cells That Target Pancreatic Adenocarcinoma Antigens Eliminate Tumors and Metastases in Mice. <i>Gastroenterology</i> , 2012, 143, 1375-1384.e5.	1.3	82
26	IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression. <i>Cancer Research</i> , 2011, 71, 5697-5706.	0.9	417
27	CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck Activation. <i>Molecular Therapy</i> , 2011, 19, 760-767.	8.2	106
28	Clinical Scale Central Memory T Cell Enrichment for Adoptive T Cell Therapy. <i>Blood</i> , 2010, 116, 5180-5180.	1.4	0
29	CD28 Costimulation of Effector T Cells During An Anti-Tumor Attack Sustains Its Repression by Regulatory T Cells Which Can Be Overcome by Preventing Lck Activation.. <i>Blood</i> , 2009, 114, 3569-3569.	1.4	0
30	T Cells Redirected Against Hepatitis B Virus Surface Proteins Eliminate Infected Hepatocytes. <i>Gastroenterology</i> , 2008, 134, 239-247.	1.3	137
31	Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17481-17486.	7.1	177
32	Impact of Regulatory T Cells on Antigen Specific T Cell Response Using Recombinant Chimeric T Cell Receptors In Vivo.. <i>Blood</i> , 2006, 108, 5475-5475.	1.4	0
33	T Cell Activation by Antibody-Like Immunoreceptors: Increase in Affinity of the Single-Chain Fragment Domain above Threshold Does Not Increase T Cell Activation against Antigen-Positive Target Cells but Decreases Selectivity. <i>Journal of Immunology</i> , 2004, 173, 7647-7653.	0.8	237